Sana Biotechnology/$SANA
1D1W1MYTD1Y5YMAX
About Sana Biotechnology
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
- Ticker
- $SANA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 142
- Headquarters
- Seattle, United States
- Website
- www.sana.com
SANA Metrics
BasicAdvanced
$1.2B
-
-$0.76
2.10
-
Price and volume
Market cap
$1.2B
Beta
2.1
52-week high
$6.55
52-week low
$2.61
Average daily volume
2.5M
Financial strength
Current ratio
1.379
Quick ratio
1.297
Long term debt to equity
42.72
Total debt to equity
52.365
Profitability
EBITDA (TTM)
-174.186
Management effectiveness
Return on assets (TTM)
-29.16%
Return on equity (TTM)
-152.87%
Valuation
Price to book
7.59
Price to tangible book (TTM)
-25.93
Price to free cash flow (TTM)
-8.051
Free cash flow yield (TTM)
-12.42%
Free cash flow per share (TTM)
-0.487
Growth
Earnings per share change (TTM)
-28.25%
3-year earnings per share growth (CAGR)
-26.13%
What the Analysts think about SANA
Analyst ratings (Buy, Hold, Sell) for Sana Biotechnology stock.
SANA Financial Performance
Revenues and expenses
SANA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.